Aliases & Classifications for Colitis

MalaCards integrated aliases for Colitis:

Name: Colitis 12 74 29 54 6 43 15 17 71

Classifications:



External Ids:

Disease Ontology 12 DOID:0060180
MeSH 43 D003092
NCIt 49 C26723
SNOMED-CT 67 64226004
ICD10 32 K52.9
UMLS 71 C0009319

Summaries for Colitis

Disease Ontology : 12 An inflammatory bowel disease that involves inflammation located in colon.

MalaCards based summary : Colitis is related to chemical colitis and microscopic colitis. An important gene associated with Colitis is NOD2 (Nucleotide Binding Oligomerization Domain Containing 2), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Tocopherol and Zinc have been mentioned in the context of this disorder. Affiliated tissues include colon, t cells and liver, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Wikipedia : 74 Colitis is an inflammation of the colon. Colitis may be acute and self-limited or long-term. It broadly... more...

Related Diseases for Colitis

Diseases related to Colitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1716)
# Related Disease Score Top Affiliating Genes
1 chemical colitis 35.1 TNF NOD2 IL17A IL10
2 microscopic colitis 35.0 TNF IL6 IL2 IFNG HLA-DRB1
3 crohn's colitis 34.8 TNF NOD2 IL2 IL1B IFNG CXCL8
4 ulcerative colitis 34.4 TNF SMAD4 REL NOD2 MPO IRGM
5 amebiasis 34.2 TNF IL17A CXCL8
6 inflammatory bowel disease 1 34.1 TNF NOD2 IRGM IL6 IL23R ATG16L1
7 inflammatory bowel disease 25, autosomal recessive 33.8 IL10RB IL10RA IL10
8 crohn's disease 33.8 TNF NOD2 IRGM IL6 IL23R IL2
9 cholangitis, primary sclerosing 33.5 TNF NOD2 MPO IL6
10 gastroenteritis 33.5 TNF IL6 IL1B IL10 IFNG CXCL8
11 pouchitis 33.4 NOD2 CXCL8
12 irritable bowel syndrome 33.4 TNF IL6 IL10 CXCL8
13 pyoderma gangrenosum 33.4 TNF NOD2 CXCL8
14 inflammatory bowel disease 33.0 TNF REL NOD2 MPO IRGM IL6
15 ileocolitis 32.7 TNF NOD2 ATG16L1
16 ileitis 32.5 TNF NOD2 MPO IL6 IL17A IL10
17 diarrhea 32.4 TNF MPO IL6 IL2 IL1B IL10
18 proctitis 32.3 TNF MPO ABCB1
19 sclerosing cholangitis 32.1 TNF NOD2 MPO IL6 IL2 IL10
20 pyoderma 32.1 TNF NOD2 CXCL8
21 colorectal cancer 32.1 TNF SMAD4 NOD2 MPO IL6 IL2
22 cholangitis 32.0 TNF NOD2 MPO IL6 IL2 IL17A
23 vasculitis 31.9 TNF MPO IL6 IL17A
24 cytomegalovirus infection 31.9 TNF IL6 IL1B CXCL8
25 hypereosinophilic syndrome 31.8 MPO IL2 IL10 IFNG CXCL8
26 dysentery 31.7 TNF IL6 IL1B IL10 CXCL8
27 peritonitis 31.7 TNF MPO IL6 IL1B IL10 IFNG
28 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 31.6 IL17A IL10 IFNG
29 autoimmune disease 31.6 TNF IL6 IL23R IL2 IL1B IL17A
30 allergic hypersensitivity disease 31.6 TNF IL2 IL17A IL10 IFNG CXCL8
31 severe combined immunodeficiency 31.6 IL6 IL2 IL17A IL10 IFNG
32 spondyloarthropathy 1 31.6 TNF NOD2 IL23R IL17A
33 gastritis 31.6 TNF IL6 IL1B IL17A IL10 CXCL8
34 pustulosis of palm and sole 31.5 TNF IL17A CXCL8
35 proteasome-associated autoinflammatory syndrome 1 31.5 TNF MPO IL6 IL1B IL17A IL10
36 acute pancreatitis 31.5 TNF MPO IL6 IL1B IL10 CXCL8
37 purpura 31.4 TNF IL6 IL10
38 ileus 31.4 TNF IL6 IL1B IL17A IL10 IFNG
39 liver disease 31.4 TNF IL6 IL1B CXCL8 AKT1
40 acquired immunodeficiency syndrome 31.4 TNF IL6 IL2 IL1B IL10 IFNG
41 peptic ulcer disease 31.4 TNF IL1B IL10 CXCL8
42 exanthem 31.4 TNF IL6 IL2 IL10 CXCL8 AKT1
43 thyroiditis 31.4 TNF IL6 IL2 IL10
44 immune deficiency disease 31.4 TNF REL IL6 IL2 IL10 IFNG
45 celiac disease 1 31.4 TNF NOD2 IL6 IL23R IL2 IL17A
46 esophagitis 31.4 TNF IL6 IL1B IL10 CXCL8
47 sarcoidosis 1 31.4 TNF NOD2 IL2 IL1B IFNG HLA-DRB1
48 graft-versus-host disease 31.3 TNF IL6 IL2 IL1B IL10 IFNG
49 spondylitis 31.3 TNF NOD2 IL6 IL23R IL17A IL10
50 bronchiectasis 31.3 TNF MPO IL6 CXCL8

Graphical network of the top 20 diseases related to Colitis:



Diseases related to Colitis

Symptoms & Phenotypes for Colitis

GenomeRNAi Phenotypes related to Colitis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.88 AKT1 CXCL8 IL10 IL17A IL1B IL2
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.88 AKT1 CXCL8 IL10 IL17A IL1B IL2

MGI Mouse Phenotypes related to Colitis:

45 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.41 ABCB1 AKT1 ATG16L1 IFNG IL10 IL10RA
2 homeostasis/metabolism MP:0005376 10.39 ABCB1 AKT1 ATG16L1 IFNG IL10 IL10RA
3 digestive/alimentary MP:0005381 10.37 ABCB1 ATG16L1 IFNG IL10 IL10RA IL10RB
4 growth/size/body region MP:0005378 10.37 ABCB1 AKT1 ATG16L1 IFNG IL10 IL10RB
5 immune system MP:0005387 10.36 ABCB1 AKT1 ATG16L1 IFNG IL10 IL10RA
6 cardiovascular system MP:0005385 10.33 ABCB1 AKT1 ATG16L1 IFNG IL10 IL1B
7 cellular MP:0005384 10.31 AKT1 ATG16L1 IFNG IL10 IL10RA IL10RB
8 endocrine/exocrine gland MP:0005379 10.29 ABCB1 AKT1 ATG16L1 IFNG IL10 IL10RB
9 mortality/aging MP:0010768 10.2 ABCB1 AKT1 ATG16L1 IFNG IL10 IL10RB
10 liver/biliary system MP:0005370 10.07 ABCB1 AKT1 IFNG IL10 IL10RB IL2
11 integument MP:0010771 10.06 AKT1 IFNG IL10 IL17A IL1B IL6
12 muscle MP:0005369 9.86 AKT1 ATG16L1 IFNG IL10 IL6 MPO
13 neoplasm MP:0002006 9.81 AKT1 IFNG IL10 IL1B IL2 IL23R
14 respiratory system MP:0005388 9.61 AKT1 IFNG IL10 IL10RB IL17A IL2
15 skeleton MP:0005390 9.32 AKT1 IFNG IL10 IL17A IL1B IL6

Drugs & Therapeutics for Colitis

Drugs for Colitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 500)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
2
Zinc Approved, Investigational Phase 4 7440-66-6 32051
3
Copper Approved, Investigational Phase 4 7440-50-8 27099
4
Adalimumab Approved Phase 4 331731-18-1 16219006
5
Ganciclovir Approved, Investigational Phase 4 82410-32-0 3454
6
Iron Approved, Experimental Phase 4 7439-89-6, 15438-31-0 23925 27284
7
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
8
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
9
Cefpirome Approved Phase 4 84957-29-9 5479539
10
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
11
Moxifloxacin Approved, Investigational Phase 4 151096-09-2, 354812-41-2 152946
12
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
13
Polyestradiol phosphate Approved Phase 4 28014-46-2
14
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
15
Linaclotide Approved Phase 4 851199-59-2 65351
16
Tofacitinib Approved, Investigational Phase 4 477600-75-2
17
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
18
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
19
Sodium citrate Approved, Investigational Phase 4 68-04-2
20
Nicotine Approved Phase 4 54-11-5 942 89594
21
carbamide peroxide Approved Phase 4 124-43-6
22
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
23
Ursodeoxycholic acid Approved, Investigational Phase 4 128-13-2 31401
24
Magnesium citrate Approved Phase 4 3344-18-1
25
Losartan Approved Phase 4 114798-26-4 3961
26
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
27
Dextromethorphan Approved Phase 4 125-71-3 5360696 5362449
28
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198
29
Caffeine Approved Phase 4 58-08-2 2519
30
Ceftriaxone Approved Phase 4 73384-59-5 5479530 5361919
31
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
32
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
33
Ofloxacin Approved Phase 4 82419-36-1 4583
34
Colestipol Approved Phase 4 26658-42-4
35
Teicoplanin Approved, Investigational Phase 4 61036-62-2
36
Ustekinumab Approved, Investigational Phase 4 815610-63-0
37
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
38
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
39
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
40
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
41
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
42 Tocotrienol Investigational Phase 4 6829-55-6
43 Tocopherols Phase 4
44 Tocotrienols Phase 4
45 Polyethylene glycol 3350 Phase 4
46 Nutrients Phase 4
47 Trace Elements Phase 4
48 Micronutrients Phase 4
49 Antioxidants Phase 4
50 Vitamins Phase 4

Interventional clinical trials:

(show top 50) (show all 1517)
# Name Status NCT ID Phase Drugs
1 PREDICT UC: Optimising Infliximab Induction Therapy for Acute Severe Ulcerative Colitis - A Randomised Controlled Trial Unknown status NCT02770040 Phase 4 Infliximab
2 Efficacy of Treatment With Berberine to Maintain Remission in Ulcerative Colitis: An Open-label,Randomized,Phase IV Clinical Trial Unknown status NCT02962245 Phase 4 berberine;regular treatment
3 Santeon InflixMab biosimILAr Research A Randomized, Controlled, Double Blind, Phase 4 Noninferiority Trial to Assess Efficacy of Infliximab-biosimilar (Inflectra) Compared to Infliximab-innovator (Remicade) in Patients With Inflammatory Bowel Disease in Remission. Unknown status NCT02452151 Phase 4 Infliximab-Biosimilar;Infliximab-Innovator
4 Pilot Study to Evaluate the Efficacy of Golimumab for Induction and Maintenance of Clinical and Endoscopic Remission in Patients With Steroid-dependent Ulcerative Colitis Unknown status NCT02412085 Phase 4 Golimumab
5 Fecal Microbiota Transplantation for Ulcerative Colitis Through Colonic Transendoscopic Enteral Tubing Unknown status NCT02998112 Phase 4 fecal microbiota transplantation;Saline
6 Combination Corticosteroids + 5-aminosalicylic Acids Compared to Corticosteroids Alone in the Treatment of Moderate-severe Active Ulcerative Colitis. Unknown status NCT01941589 Phase 4 oral 5-ASA+/-topical 5-ASA+IV corticosteroids / PO Methylprednisolone;corticosteroids only
7 A Randomized, Double-blind Study Investigating the Efficacy and Safety of Mesalazine With Hydrocortisone Sodium Succinate (100mg QD) Enema for 4-Week Treatment in Patients With Ulcerative Colitis (UC) Unknown status NCT03110198 Phase 4 Mesalazine;hydrocortisone sodium succinate;Mesalazine with hydrocortisone sodium succinate
8 Probiotic for the Restoration of Intestinal Permeability and Reduction of Intestinal Inflammation in Active Ulcerative Colitis: A Double Blind Randomized Placebo Controlled Trial Unknown status NCT01479660 Phase 4 Probiotic
9 Personalised Medicine: a Break Through Approach for Early Determination of Anti Tumor Necrosis Factor (TNF) Responders and Non Responders Among Patients With Ulcerative Colitis in a Prospective Study With Golimumab (Simponi) Unknown status NCT02186886 Phase 4 Golimumab
10 Brief Escalation of Adalimumab Treatment for Prevention of Clinical Relapse in IBD Unknown status NCT03059849 Phase 4 Adalimumab
11 The Effect of Probiotics on the Rate of Recovery of Inflammatory Bowel Disease Exacerbation (Crohn's Disease) and Markers of Inflammation Unknown status NCT01765998 Phase 4 Probiotic;Placebo
12 Randomized Cross-Over Trial of Captafer® vs. Oral Iron Sulfate in the Treatment of Iron Deficiency Anemia in Patients With Inflammatory Bowel Disease Unknown status NCT02774057 Phase 4 Captafer®;Iron Sulfate
13 The Effect of Probiotics on Bowel Disease Unknown status NCT01078935 Phase 4
14 Efficacy of Proklama on Patients' Symptoms With Irritable Bowel Syndrome: Clinical Trial, Double- Blind, Crossover, Controlled Study vs. Placebo Unknown status NCT02573844 Phase 4 Proklama
15 A Prospective Multi-centric Belgian Trial to Validate the Use of Golimumab Serum Level Analysis Using the Dried Blood Spot (DBS) Methodology Unknown status NCT02910375 Phase 4
16 Anemia Treatment in Inflammatory Bowel Disease: Predictive Factors of Response to Oral Iron Treatment Unknown status NCT02760940 Phase 4 oral liposomal iron
17 A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease Unknown status NCT01632462 Phase 4 VSL#3
18 COLITIS: Clostridial Infection and Oral Lavage -Improving Treatment Before Illness Becomes Severe Unknown status NCT01630096 Phase 4 Nu-Lytely
19 Bacteria and Cytokines as Factors Modulating Visceral Afferent Processing in Irritable Bowel Syndrome: Manipulation of Intestinal Bacteria and Mucosal Cytokines by Probiotic Therapy and the Effect on Visceral Hypersensitivity Unknown status NCT00418340 Phase 4 probiotic (bacterial/dietary supplement)
20 Study for the Treatment of Ulcerative Colitis With Adacolumn (Companion to US Study 512-04-205) Completed NCT00219414 Phase 4
21 Preference for a Prefilled Syringe or Smartject™ Device for Delivering SIMPONI (Golimumab) in Patients Suffering From Moderate to Severe Ulcerative Colitis Completed NCT02155335 Phase 4 Prefilled Syringe delivery of Golimumab;Smartject Device delivery of Golimumab
22 Multicentre Investigation of the Efficacy and Safety of Adacolumn® GMA in Patients With Steroid-Dependent Active Ulcerative Colitis and Insufficient Response or Intolerance to Immunosuppressants and/or Biological Therapies Completed NCT01481142 Phase 4
23 A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SWITCHING FROM INNOVATOR INFLIXIMAB TO BIOSIMILAR INFLIXIMAB COMPARED WITH CONTINUED TREATMENT WITH INNOVATOR INFLIXIMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS, SPONDYLOARTHRITIS, PSORIATIC ARTHRITIS, ULCERATIVE COLITIS, CROHN'S DISEASE AND CHRONIC PLAQUE PSORIASIS THE NOR-SWITCH STUDY Completed NCT02148640 Phase 4 Innovator infliximab;Biosimilar infliximab
24 A Phase IV, Multi-center, Open-label Study to Assess Clinical Recurrence Related to Compliance With Treatment With MMX Mesalamine 2.4g/Day Given Once Daily for the Maintenance of Quiescent Ulcerative Colitis (UC) Completed NCT00446849 Phase 4 MMX Mesalamine
25 Golimumab: A Phase 4, UK, Open Label, Single Arm Study on Its Utilization and Impact in Ulcerative Colitis Completed NCT02092285 Phase 4 Golimumab
26 A Randomized, Multicenter Open Label Study Comparing Cyclosporine With Infliximab in Steroid-refractory Severe Attacks of Ulcerative Colitis Completed NCT00542152 Phase 4 CYCLOSPORINE VS INFLIXIMAB
27 Active Ulcerative Colitis; Placebo Controlled Treatment Trial With Ciprofloxacin and E. Coli Nissle Completed NCT01772615 Phase 4 Ciprofloxacin
28 An Open Label, Single Group Assignment Design Study to Correlate Soluble ST2 With Clinical, Endoscopic and Histological Activity in Moderate to Severe Ulcerative Colitis Patients Under Golimumab. Completed NCT02318667 Phase 4
29 An Open-Label, Multicenter and Open Enrollment Model, Postmarketing, Milk-Only Lactation Study to Assess Concentration of Vedolizumab in Breast Milk of Lactating Women With Active Ulcerative Colitis or Crohn's Disease Who Are Receiving Vedolizumab Therapeutically Completed NCT02559713 Phase 4 Vedolizumab
30 Histological and Endoscopic Evaluation of Remission Induced by Infliximab in Moderately to Severely Active Ulcerative Colitis Patients Completed NCT01408810 Phase 4 Infliximab
31 Immunogenicity of Hepatitis A Vaccine in Patients With Inflammatory Bowel Disease Completed NCT01341808 Phase 4
32 Test Treat Strategy to Prevent Ulcerative Colitis Relapse Completed NCT00652145 Phase 4 mesalamine
33 Impact of Six Patient Information Leaflets (PIL) on Doctor Patient Communication and Adherence in Emergency Ward Completed NCT02246361 Phase 4
34 A Phase 4, Open-label, Multicenter, Prospective Study to Evaluate the Effect of Remission Status on the Ability to Maintain or Achieve Clinical and Endoscopic Remission During a 12-Month, Long-term Maintenance Phase With 2.4g/Day MMX Mesalamine/Mesalazine Once Daily in Adult Subjects With Ulcerative Colitis Completed NCT01124149 Phase 4 MMX mesalamine/ mesalazine
35 Multi Center Ulcerative Colitis Pediatric Pentasa Intervention Trial (MUPPIT). A Randomized, Single-blinded, Controlled, Parallel, Induction Therapy With Once vs. Twice Daily Dosing of Pentasa in Pediatric UC. Completed NCT01201122 Phase 4 Mesalamine
36 Colon Cleasing for Colonoscopy in Patients With IBD Colitis: Efficacy and Acceptability of 4 Liter PEG vs 2 Liter PEG Plus Bisacodil Completed NCT02248337 Phase 4 Colon preparation for colonoscopy
37 Steroid-induced Mood Changes in Patients With Inflammatory Bowel Disease Completed NCT01981889 Phase 4 Prednisone
38 Open Label Safety and Efficacy Trial of Twice Daily Dosing of Asacol vs. Three Times Per Day Dosing for the Induction of Remission in Active Ulcerative Colitis Completed NCT00194818 Phase 4 Asacol (mesalamine)
39 Multicenter Open-label Study Evaluating the Safety and Efficacy of Standardized Initial Therapy Using Either Mesalamine or Corticosteroids Then Mesalamine to Treat Children and Adolescents With Newly Diagnosed Ulcerative Colitis. Completed NCT01536535 Phase 4 Mesalazine;IV Corticosteroid;Oral Corticosteroids
40 The Influence of 5–Aminosalicylates on Thiopurine Metabolite Levels Completed NCT00167882 Phase 4 5-aminosalicylate (Pentasa, Ferring)
41 Safety of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease: A Prospective, Randomized, Double-Blind, Controlled Trial Completed NCT01346826 Phase 4 Standard 2 hours-infusion;Accelerated 1 hour-infusion;Accelerated 30 minutes-infusion
42 Serological Response to Pneumococcal Vaccination in Crohn's Disease: A Prospective Multicenter Study Completed NCT01505855 Phase 4 23-valent polysaccharide pneumococcal vaccine
43 Randomized Trial of High Dose vs. Standard Dose Influenza Vaccine in Inflammatory Bowel Disease Patients Completed NCT02461758 Phase 4
44 Lactobacillus Casei e Bifidobacterium Breve as Probiotics at the Treatment of Antibiotic Associated Diarrhea: a Randomized Double Blind Study Completed NCT00700557 Phase 4
45 A Randomised Placebo Controlled Trial of "Follow on" Rifaximin for the Prevention of Relapse of Clostridium Associated Diarrhoea Completed NCT01670149 Phase 4 Rifaximin;Placebo
46 Treatment of Iron Deficiency Anaemia in Adults and Adolescents With Inflammatory Bowel Disease Using Ferrous Sulphate: Tolerance and Effects on Haemoglobin, Mood, Quality of Life and Fatigue Completed NCT01991314 Phase 4 Ferrous sulphate
47 Precision Dosing Versus Conventional Dosing of Infliximab Maintenance Therapy: a Randomized Controlled Multicenter Study in Patients With IBD in Clinical Remission Completed NCT02453776 Phase 4 PRECISION dosing Infliximab
48 Comparison of Immune Response to the Human Papillomavirus Vaccine in Young Women With and Without Inflammatory Bowel Disease Completed NCT01034358 Phase 4
49 A Multi-centre Double Blind Randomised Placebo-controlled Study of the Use of Rectal Tacrolimus in the Treatment of Resistant Ulcerative Proctitis Completed NCT01418131 Phase 4 Rectal tacrolimus;Placebo
50 Treating Disrupted Sleep in Individuals With Inflammatory Bowel Disease: A Novel Adjunctive Therapy for Chronic Inflammatory Illness Completed NCT02162862 Phase 4 bupropion-SR

Search NIH Clinical Center for Colitis

Cochrane evidence based reviews: colitis

Genetic Tests for Colitis

Genetic tests related to Colitis:

# Genetic test Affiliating Genes
1 Colitis 29

Anatomical Context for Colitis

The Foundational Model of Anatomy Ontology organs/tissues related to Colitis:

19
Colon

MalaCards organs/tissues related to Colitis:

40
Colon, T Cells, Liver, Neutrophil, Bone, Testes, Monocytes

Publications for Colitis

Articles related to Colitis:

(show top 50) (show all 30274)
# Title Authors PMID Year
1
Probiotic yeasts: anti-inflammatory potential of various non-pathogenic strains in experimental colitis in mice. 54 61
20440854 2010
2
Colitis as a manifestation of infliximab-associated disseminated cryptococcosis. 54 61
19660974 2010
3
On the benefit of Teucrium in murine colitis through improvement of toxic inflammatory mediators. 54 61
20144954 2010
4
Tumor necrosis factor and interferon-gamma down-regulate Klotho in mice with colitis. 54 61
20004202 2010
5
Cutting edge: IFN-gamma is a negative regulator of IL-23 in murine macrophages and experimental colitis. 54 61
20228197 2010
6
Induction of IDO-1 by immunostimulatory DNA limits severity of experimental colitis. 54 61
20181893 2010
7
TLR5 is not required for flagellin-mediated exacerbation of DSS colitis. 54 61
19774646 2010
8
Enoxaparin improves the course of dextran sodium sulfate-induced colitis in syndecan-1-deficient mice. 54 61
20008145 2010
9
A feed-forward loop involving hyaluronic acid and toll-like receptor-4 as a treatment for colitis? 54 61
19879211 2009
10
Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab. 54 61
19104936 2009
11
The gut feeling of Treg cells: IL-10 is the silver lining during colitis. 54 61
19841645 2009
12
All-trans retinoic acid down-regulates inflammatory responses by shifting the Treg/Th17 profile in human ulcerative and murine colitis. 54 61
19477911 2009
13
Methotrexate is effective in reactivated colitis and reduces inflammatory alterations in mesenteric adipose tissue during intestinal inflammation. 54 61
19450685 2009
14
Supplemental calcium attenuates the colitis-related increase in diarrhea, intestinal permeability, and extracellular matrix breakdown in HLA-B27 transgenic rats. 54 61
19535420 2009
15
Piroxicam accelerates development of colitis in T-cell receptor alpha chain-deficient mice. 54 61
19446544 2009
16
Blocking CD27-CD70 costimulatory pathway suppresses experimental colitis. 54 61
19525396 2009
17
Citrobacter rodentium colitis evokes post-infectious hyperexcitability of mouse nociceptive colonic dorsal root ganglion neurons. 54 61
19470777 2009
18
A novel Toll-like receptor 4 antagonist antibody ameliorates inflammation but impairs mucosal healing in murine colitis. 54 61
19359427 2009
19
Sleep deprivation worsens inflammation and delays recovery in a mouse model of colitis. 54 61
19403332 2009
20
Mitogen-activated protein kinase pathways contribute to hypercontractility and increased Ca2+ sensitization in murine experimental colitis. 54 61
19190174 2009
21
Minocycline attenuates experimental colitis in mice by blocking expression of inducible nitric oxide synthase and matrix metalloproteinases. 54 61
19285099 2009
22
Modulation of inflammatory response via alpha2-adrenoceptor blockade in acute murine colitis. 54 61
19250273 2009
23
Contribution of adenosine A2B receptors to inflammatory parameters of experimental colitis. 54 61
19342675 2009
24
Nitric oxide increases Wnt-induced secreted protein-1 (WISP-1/CCN4) expression and function in colitis. 54 61
19238344 2009
25
Tumor necrosis factor-alpha impairs intestinal phosphate absorption in colitis. 54 61
19196948 2009
26
The effect of Saccharomyces boulardii on human colon cells and inflammation in rats with trinitrobenzene sulfonic acid-induced colitis. 54 61
18612822 2009
27
Dietary taurine attenuates dextran sulfate sodium (DSS)-induced experimental colitis in mice. 54 61
19239157 2009
28
A role for sphingosine kinase 1 in dextran sulfate sodium-induced colitis. 54 61
18815359 2009
29
Protection from DNBS-induced colitis by the tachykinin NK(1) receptor antagonist SR140333 in rats. 54 61
19103194 2009
30
[Free hemoglobin and tumor necrosis factor-alpha in the blood of horses with colic or acute colitis]. 54 61
19086694 2008
31
Tetomilast suppressed production of proinflammatory cytokines from human monocytes and ameliorated chronic colitis in IL-10-deficient mice. 54 61
18618633 2008
32
Treatment with bindarit, an inhibitor of MCP-1 synthesis, protects mice against trinitrobenzene sulfonic acid-induced colitis. 54 61
18827968 2008
33
Treatment of severe steroid refractory ulcerative colitis. 54 61
18810767 2008
34
Blockade of adenosine A2B receptors ameliorates murine colitis. 54 61
18536750 2008
35
Substance P-mediated expression of the pro-angiogenic factor CCN1 modulates the course of colitis. 54 61
18599605 2008
36
The transcription factor IFN regulatory factor-4 controls experimental colitis in mice via T cell-derived IL-6. 54 61
18535667 2008
37
Tumour necrosis factor alpha in segmental colitis associated with diverticula. 54 61
18049899 2008
38
Suppressor of cytokine signaling-1 ameliorates dextran sulfate sodium-induced colitis in mice. 54 61
18381351 2008
39
Cytomegalovirus colitis in a patient with Behcet's disease receiving tumor necrosis factor alpha inhibitory treatment. 54 61
18473420 2008
40
Interleukin-23 restrains regulatory T cell activity to drive T cell-dependent colitis. 54 61
18400195 2008
41
Human leucocyte antigen and TNFalpha polymorphism association in microscopic colitis. 54 61
18334870 2008
42
Role of M-CSF-dependent macrophages in colitis is driven by the nature of the inflammatory stimulus. 54 61
18202111 2008
43
Aberrant mucin assembly in mice causes endoplasmic reticulum stress and spontaneous inflammation resembling ulcerative colitis. 54 61
18318598 2008
44
Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. 54 61
18219394 2008
45
IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. 54 61
18172556 2008
46
Downregulation of CPI-17 contributes to dysfunctional motility in chronic intestinal inflammation model mice and ulcerative colitis patients. 54 61
19012039 2008
47
Systemic, but not intestinal, IL-7 is essential for the persistence of chronic colitis. 54 61
18097039 2008
48
Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. 54 61
18054559 2007
49
5-aminosalicylic acid given in the remission stage of colitis suppresses colitis-associated cancer in a mouse colitis model. 54 61
17975166 2007
50
Curcumin prevents the development of dextran sulfate Sodium (DSS)-induced experimental colitis. 54 61
17429738 2007

Variations for Colitis

ClinVar genetic disease variations for Colitis:

6 ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 CHEK2 NM_007194.4(CHEK2):c.1100del (p.Thr367fs)deletion Conflicting interpretations of pathogenicity 128042 rs555607708 22:29091857-29091857 22:28695869-28695869
2 FLNA NM_001110556.2(FLNA):c.7463C>A (p.Thr2488Asn)SNV Uncertain significance 465020 rs909387820 X:153578106-153578106 X:154349738-154349738
3 CIITA NM_000246.3(CIITA):c.3344G>A (p.Ser1115Asn)SNV Uncertain significance 598994 rs138790505 16:11017111-11017111 16:10923254-10923254

Expression for Colitis

Search GEO for disease gene expression data for Colitis.

Pathways for Colitis

Pathways related to Colitis according to GeneCards Suite gene sharing:

(show top 50) (show all 101)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.17 TNF REL NOD2 MPO IL6 IL23R
2
Show member pathways
13.96 TNF SMAD4 IL6 IL23R IL2 IL1B
3
Show member pathways
13.83 TNF SMAD4 IL6 IL23R IL2 IL1B
4
Show member pathways
13.7 TNF SMAD4 IL6 IL2 IL1B IL17A
5
Show member pathways
13.57 TNF IL6 IL23R IL2 IL1B IL17A
6
Show member pathways
13.45 TNF SMAD4 IL6 IL23R IL2 IL1B
7
Show member pathways
13.41 TNF NOD2 IL6 IL23R IL2 IL1B
8
Show member pathways
13.29 TNF SMAD4 REL NOD2 IL6 IL2
9
Show member pathways
13.08 TNF IL6 IL1B IL10RB IL10RA CXCL8
10
Show member pathways
13.01 TNF IL6 IL2 IL1B IL17A IL10
11
Show member pathways
13 TNF IL6 IL2 IL1B IFNG HLA-DRB1
12 12.99 SMAD4 IL6 IL23R IL2 IFNG CXCL8
13 12.92 TNF IL6 IL1B IFNG HLA-DRB1 AKT1
14
Show member pathways
12.89 TNF REL IL6 IL1B IFNG CXCL8
15
Show member pathways
12.84 TNF REL IL6 IL2 IL1B AKT1
16
Show member pathways
12.83 TNF REL IL2 IL10RB IL10RA IL10
17
Show member pathways
12.79 TNF REL IL6 IL2 IL1B IL17A
18
Show member pathways
12.76 TNF REL IL1B IFNG AKT1
19 12.76 TNF REL MPO IL2 IL1B IL17A
20
Show member pathways
12.54 TNF IL6 IL2 IL10RB IL10RA IL10
21
Show member pathways
12.53 TNF REL IL6 IL1B IL17A IFNG
22 12.52 TNF IL1B CXCL8 ATG16L1 AKT1
23 12.52 TNF SMAD4 IL6 IL2 HLA-DRB1 AKT1
24
Show member pathways
12.52 IL6 IL23R IL2 IL10RB IL10RA IL10
25
Show member pathways
12.51 TNF MPO IL6 IL2 IL1B IFNG
26
Show member pathways
12.49 TNF IL6 IL1B IFNG CXCL8 AKT1
27
Show member pathways
12.44 TNF IL6 IL2 IL1B IL17A IL10
28 12.43 TNF NOD2 IL6 IL1B CXCL8 ATG16L1
29
Show member pathways
12.41 TNF REL IL6 IL2 IL1B IL10
30
Show member pathways
12.39 REL NOD2 IL1B AKT1
31 12.38 TNF IL6 IL1B CXCL8
32
Show member pathways
12.38 TNF REL IL6 IL1B CXCL8
33
Show member pathways
12.38 TNF REL IL6 IL1B IFNG CXCL8
34
Show member pathways
12.35 TNF REL IL6 CXCL8
35 12.35 TNF SMAD4 IL6 IFNG AKT1
36 12.34 REL MPO IL6 CXCL8
37 12.34 TNF IL6 IL1B IL10 CXCL8
38
Show member pathways
12.33 TNF IRGM IL1B IL10RB IL10RA IL10
39
Show member pathways
12.27 TNF SMAD4 NOD2 IL6 IL23R IL2
40 12.23 TNF IL6 IL2 IL1B IFNG CXCL8
41 12.23 TNF IL6 IL2 IL1B IL10 CXCL8
42 12.21 TNF MPO IL6 IL2 IL10 IFNG
43 12.2 TNF IL1B IFNG AKT1
44
Show member pathways
12.2 SMAD4 IL6 IL10 AKT1
45 12.16 TNF IL1B IFNG AKT1
46
Show member pathways
12.16 TNF IL6 IL1B IFNG
47
Show member pathways
12.16 REL IL2 IL1B IFNG HLA-DRB1
48 12.16 SMAD4 IL6 IL1B IFNG CXCL8 ATG16L1
49 12.15 TNF NOD2 IL6 IL1B AKT1
50 12.14 TNF IL6 IL1B IL10 IFNG CXCL8

GO Terms for Colitis

Cellular components related to Colitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.28 TNF MPO IL6 IL2 IL1B IL17A

Biological processes related to Colitis according to GeneCards Suite gene sharing:

(show top 50) (show all 66)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 10.17 TNF SMAD4 REL IL6 IL1B IL10
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.16 TNF SMAD4 REL NOD2 IL6 IL2
3 positive regulation of cell proliferation GO:0008284 10.15 NOD2 IL6 IL2 IL1B IFNG AKT1
4 positive regulation of gene expression GO:0010628 10.13 TNF IL6 IL1B IFNG AKT1
5 negative regulation of cell proliferation GO:0008285 10.13 SMAD4 IL6 IL1B IL10 CXCL8
6 defense response to bacterium GO:0042742 10.04 TNF NOD2 MPO IRGM IL10
7 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 10.01 TNF REL NOD2 IL1B
8 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.99 TNF NOD2 IL6 IL1B
9 response to lipopolysaccharide GO:0032496 9.99 MPO IL23R IL1B IL10RA IL10
10 defense response GO:0006952 9.96 TNF NOD2 MPO IRGM CXCL8
11 positive regulation of protein phosphorylation GO:0001934 9.95 TNF IRGM IL2 IL1B IFNG AKT1
12 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.93 TNF IRGM IL6 AKT1
13 regulation of insulin secretion GO:0050796 9.9 TNF IL1B IFNG
14 response to glucocorticoid GO:0051384 9.9 TNF IL6 IL10
15 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.9 TNF REL AKT1
16 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.9 TNF NOD2 IL1B
17 cellular response to organic cyclic compound GO:0071407 9.9 TNF NOD2 IL1B AKT1
18 positive regulation of smooth muscle cell proliferation GO:0048661 9.89 TNF IL6 AKT1
19 humoral immune response GO:0006959 9.89 TNF IL6 IFNG
20 positive regulation of DNA-binding transcription factor activity GO:0051091 9.89 TNF IL6 IL1B IL10 AKT1
21 positive regulation of protein localization to plasma membrane GO:1903078 9.88 TNF IFNG AKT1
22 negative regulation of autophagy GO:0010507 9.88 IL10RA IL10 AKT1
23 positive regulation of autophagy GO:0010508 9.88 IRGM IFNG ATG16L1
24 positive regulation of T cell proliferation GO:0042102 9.88 IL6 IL23R IL2 IL1B
25 positive regulation of phagocytosis GO:0050766 9.87 TNF IL1B IFNG
26 positive regulation of epithelial to mesenchymal transition GO:0010718 9.87 SMAD4 IL6 IL1B
27 positive regulation of interleukin-6 production GO:0032755 9.87 TNF NOD2 IL6 IL1B
28 cellular response to lipopolysaccharide GO:0071222 9.87 TNF NOD2 IRGM IL6 IL1B IL10
29 protein kinase B signaling GO:0043491 9.85 TNF IL1B AKT1
30 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.85 TNF IL1B AKT1
31 positive regulation of interleukin-6 secretion GO:2000778 9.85 TNF IL1B IL17A
32 immune response GO:0006955 9.85